Aptose Biosciences Files 8-K on Financials
Ticker: APTOF · Form: 8-K · Filed: Mar 26, 2024 · CIK: 882361
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: APTO
TL;DR
APTO filed an 8-K on March 26th detailing financial condition and results of operations.
AI Summary
Aptose Biosciences Inc. filed an 8-K on March 26, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Toronto, Canada.
Why It Matters
This filing provides crucial updates on Aptose Biosciences' financial health and operational status, which can influence investor decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- March 26, 2024 (date) — Date of earliest event reported
- Toronto, Canada (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?
The primary purpose is to report on the company's results of operations and financial condition, as well as to file financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 26, 2024.
Where are Aptose Biosciences Inc.'s principal executive offices located?
Aptose Biosciences Inc.'s principal executive offices are located in Toronto, Canada.
What is the Standard Industrial Classification code for Aptose Biosciences Inc.?
The Standard Industrial Classification code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Has Aptose Biosciences Inc. undergone any former company name changes?
Yes, Aptose Biosciences Inc. was formerly known as LORUS THERAPEUTICS INC. (name change on 20140905) and prior to that, IMUTEC PHARMA INC (name change on 19970113).
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-03-26 16:04:15
Filing Documents
- f8k_032624.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 49KB
- 0001171843-24-001603.txt ( ) — 268KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_032624_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 26, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit 99.1 Press Release dated March 26, 2024 Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: March 26, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer